UXN Co., Ltd.
KKRX:3378406,150.00
KRW
+40.00
(+0.65%)
ISIN
KR7337840003
Return %
Stock
S&P 500
1Y
-32.86
14.39
3Y
-62.04
81.42
5Y
-74.80
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sae-Jin Park
- Full Time Employees
- 26
- Sector
- Electronic technology
- Industry
- Aerospace & defense
- Address
- Uiwang-si South Korea
- IPO Date
- Nov 28, 2019
- Website
- uxn.co.kr
- Similar Companies
- Business
- UXN Co., Ltd. is a South Korea-based medical technology and biotechnology company specializing in the research, development, and commercialization of continuous glucose monitoring systems and advanced electrochemical biosensors. Founded in 2012 and headquartered in Seoul, South Korea, the company operates within the in-vitro diagnostics and wearable medical device sectors, serving diabetic patients, clinical healthcare providers, and research institutions across domestic and international markets. The company's core product and service portfolio comprises enzyme-free continuous glucose monitoring systems utilizing proprietary nanoporous platinum sensor technology, offering extended operational lifespan and ambient temperature storage without requiring cold-chain distribution; wearable biometric sensor patches and low-profile wireless transmitters for continuous interstitial glucose measurement; electrochemical biosensor probes and electrodes for point-of-care diagnostics and clinical laboratory testing; integrated digital healthcare software solutions, including mobile applications and cloud-enabled data management platforms that deliver real-time glucose tracking, predictive trend analytics, alert notifications, and remote monitoring capabilities for clinicians and patients; multi-analyte continuous biosensing modules designed for real-time monitoring of glucose, lactate, and ketone biomarkers in critical care and metabolic health applications; and custom biosensor development, engineering, and manufacturing services for global healthcare partners. In recent operational developments, UXN Co., Ltd. established a comprehensive strategic partnership and secured substantial equity investment from global in-vitro diagnostics leader SD Biosensor Inc. to accelerate international clinical trials, regulatory approvals, and worldwide distribution of its continuous glucose monitoring product line. The company has advanced clinical evaluation programs for its flagship enzyme-free continuous glucose monitor to obtain commercial clearances from the South Korean Ministry of Food and Drug Safety and overseas regulatory authorities. Additionally, UXN Co., Ltd. expanded its automated mass-manufacturing infrastructure for precision nanoporous electrode fabrication, extended its international patent portfolio across North America, Europe, and Asia, and advanced strategic preparations to transition its public listing from the KONEX board to the KOSDAQ market of the Korea Exchange to support global commercial scaling.